Wilcrest Pharma, a newly formed, Houston-based 503B outsourcing facility specializing in producing antineoplastic medications and mitigating drug shortages, has named A.J. Day, PharmD, as its chief executive officer. Day, a dedicated advocate for compounded medicine and patient access, brings a long record of experience in regulatory affairs and compounding supply chain, which will be essential in driving the company's growth and advancing its product portfolio.